Details of Disease

General Information of Disease (ID: DISYD5IX)

• Disease Name: Bone marrow transplantation
• Disease Class: QB63: Transplanted organ/tissue
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISYD5IX: Bone marrow transplantation
• ICD Code:
  ICD-11: ICD-11: QB63.6
  ICD-9: ICD-9: 279.5, 996
  Expand ICD-9: 279.5,996

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Immune globulin	DMX2OMJ	Approved	NA	[1]
Sargramostim	DMY0M8J	Approved	NA	[2]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Iomab-B	DMZA47Y	Phase 3	Antibody	[3]
Low molecular weight dextran sulphate	DM6PAML	Phase 2	NA	[4]
Lupron 3-month depot	DMOK76D	Phase 2	NA	[5]
Nagrestipen	DM3E20L	Phase 1	NA	[6]

This Disease is Treated as An Indication in 5 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Oncolysin B	DMVQFKS	Discontinued in Phase 2	NA	[7]
Garnocestim	DMCZAJW	Discontinued in Phase 1	NA	[8]
MEDI-500	DMT3B4G	Terminated	NA	[9]
Promegapoietin	DMS4FG0	Terminated	NA	[10]
SDZ-89-104	DMKXK0Z	Terminated	NA	[11]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ASC-201	DM5WR0L	Investigative	NA	[12]
ATI-2341	DMLDWHP	Investigative	NA	[13]
TM-400	DM1SPOQ	Investigative	NA	[14]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7905).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034703)
• [5] ClinicalTrials.gov (NCT00275262) A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation. U.S. National Institutes of Health.
• [6] Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy. Cancer Res. 2014 Sep 15;74(18):5070-8.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001205)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010770)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006835)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010450)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003860)
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
• [14] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.